Company Growth (employees)
Biogen was founded in 1978 and is headquartered in Cambridge, US
Key People/Management at Biogen
Michel Vounatsos
CEO
Biogen Office Locations
Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Biogen Financials and Metrics
Biogen Financials
Biogen's revenue was reported to be $2.8 b in Q1, 2017
USD
Revenue (Q1, 2017) | 2.8 b |
Net income (Q1, 2017) | 747.5 m |
EBIT (Q1, 2017) | 1 b |
Market capitalization (20-Oct-2017) | 71.7 b |
Cash (31-Mar-2017) | 924 m |
Biogen's current market capitalization is $71.7 b.
- Source: Company Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 6.9 b | 9.7 b | 10.8 b | 11.4 b |
Revenue growth, % | 40% | 11% | 6% | |
R&D expense | 2 b | |||
General and administrative expense | 1.9 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.4 b | 2.5 b | 2.6 b | 2.6 b | 2.8 b | 2.7 b | 2.9 b | 3 b | 2.8 b |
R&D expense | 447.3 m | 417.2 m | 460.5 m | 490.7 m | 519.9 m | 437.3 m | 473.1 m | 529 m | 423.4 m |
General and administrative expense | 576.6 m | 570.4 m | 560.4 m | 491.9 m | 477.8 m | 497.3 m | 492.4 m | 462.7 m | 499.1 m |
Operating expense total | 1 b | 987.6 m | 1 b | 982.6 m | 997.7 m | 934.6 m | 965.5 m | 991.7 m | 922.5 m |
- Source: Company Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 602.6 m | 1.2 b | 1.3 b | 2.3 b |
Accounts Receivable | 824.4 m | 1.3 b | 1.2 b | 1.4 b |
Inventories | 659 m | 804 m | 893.4 m | 1 b |
Current Assets | 3.2 b | 4.7 b | 6.7 b | 8.7 b |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 863.2 m | 1.2 b | 1.5 b | 1.3 b | 4.1 b | 1.1 b | 1.4 b | 2.1 b | 924 m |
Accounts Receivable | 1 b | 1.1 b | 1.4 b | 1.3 b | 1.3 b | 1.4 b | 1.3 b | 1.5 b | 1.5 b |
Inventories | 715.9 m | 753.1 m | 825.3 m | 865.7 m | 918.9 m | 964.6 m | 996.4 m | 1 b | 921.6 m |
Current Assets | 3.9 b | 4.4 b | 5.3 b | 5.6 b | 9.3 b | 7.2 b | 7.4 b | 8.1 b | 6.9 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 1.9 b | 2.9 b | 3.6 b | 3.7 b |
Depreciation and Amortization | 688.2 m | 600.4 m | 682.7 m | |
Accounts Receivable | (130 m) | (510 m) | 29 m | (241.4 m) |
Inventories | (240 m) | (190 m) | (170 m) | (165.6 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 723.1 m | 856.1 m | 820.2 m | 924.8 m | 1 b | 969.2 m | 1 b | 1 b | 747.5 m |
Accounts Receivable | 1.3 b | 1.3 b | 1.4 b | 1.3 b | 1.5 b | 1.5 b | |||
Inventories | 865.7 m | 918.9 m | 964.6 m | 996.4 m | 1 b | 921.6 m | |||
Accounts Payable | 282.7 m | 251.2 m | 271.3 m | 225.9 m | 274 m | 316.4 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 379.8 k |
Financial Leverage | 1.8 x |
Biogen Operating Metrics
Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016
| FY, 2016 | |
|---|---|
Training Provided, no. of people | 40 k |
Phase III Trials | 2 |
Phase II Trials | 10 |
Phase I Trials | 4 |
Biogen Market Value History
Biogen Median Salaries
Source: 109 public H-1B filings from Biogen
Market Position of Biogen
Traffic Overview of Biogen
Biogen Online and Social Media Presence
Biogen News and Updates
September 29, 2017
Rep. Cummings to Trump: It's time to force lower prices on Biogen's new MS drug Zinbryta
Rep. Elijah Cummings, D-Md., is urging President Donald Trump to twist some arms at Biogen. The biotech's new multiple sclerosis drug Zinbryta, developed with the help of taxpayer-funded research, costs too much, he argued, and Trump should use his power to push a price cut.
September 27, 2017
Recombinant Coagulation Factors Market by Regional Analysis, Key Players and Forecast 2025
Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. Posted via Industry Today. Follow us on …
August 25, 2017
Merck KGaA to take on Biogen, Novartis with long-sought EMA nod for MS pill
Six years after regulators in both the U.S. and Europe said they wouldn’t approve Merck KGaA’s oral multiple sclerosis drug, cladribine, the German company has scored an unlikely victory, winning European approval to market it in 28 countries. But competing with more established rivals won't be easy…
August 25, 2017
Biogen, Samsung Humira copy wins EU approval
The forces of competition are mounting against Humira, the world’s best-selling drug at $16 billion in global sales, with approval of a second biosimilar in Europe.
August 24, 2017
Bioverativ taps patient social network for input on hemophilia trial design
What if companies knew patients’ top unmet needs before they began clinical trials and could factor them into studies—potentially paving the way for marketers to talk up a variety of benefits down the line? Bioverativ is about to find out.
August 16, 2017
Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock
Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.